Granules India Q4 results: Paracetamol, Ibuprofen maker's profit misses analysts' estimates; board announces 150% dividend

Granules India Q4 results: Granules India — a Hyderabad-based pharma company that makes painkiller drug Paracetamol and anti-inflammatory drug Ibuprofen — on Tuesday reported a net profit of Rs 119.6 crore for the quarter ended March 2023, missing analysts' estimates. The company's net profit marked an increase of 7.8 per cent compared with the corresponding period a year ago. 

Granules India's quarterly revenue grew 16 per cent to Rs 1,195.5 crore, according to a regulatory filing, in line with Street expectations. 

According to Zee Business research, the company's quarterly net profit was estimated at Rs 140 crore and revenue at Rs 1,137 crore.

Granules India dividend

The company's board recommended a final dividend of Re 1.5 per equity share of Re 1 — a 150 per cent payout. 

Granules India dividend history

Granules India has paid a string of payouts over the past few years, including as many as 16 dividends in just five years. 

Granules India shares: Historical performance

Granules India shares lost 8.8 per cent of their value in the March quarter, a period in which the Nifty 50 index declined 4.1 per cent.  

The stock finished 2022 with a loss of 19.8 per cent, worse than a five per cent fall in the headline index. 

Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.